BioCentury | Mar 19, 2015
Distillery Therapeutics

Therapeutics: CD19 ligand (CD19L); tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)

...et al. J. Clin. Invest.; published online Jan. 26, 2015 doi:10.1172/JCI76610 CONTACT: Fatih M. Uckun, Children's Hospital Los Angeles...
BioCentury | May 5, 2014
Product Development

Targeted cargo

...product, which delivers doxorubicin, is in preclinical testing to treat Ewing's sarcoma in partnership with Children's Hospital Los Angeles...
...LSE:AZN; NYSE:AZN), London, U.K. Bayer AG (Xetra:BAYN), Leverkusen, Germany Bind Therapeutics Inc. (NASDAQ:BIND), Cambridge, Mass. Children's Hospital Los Angeles...
BioCentury | Jul 26, 2012
Distillery Therapeutics

Indication: Various

...published online July 9, 2012; doi:10.1172/JCI62888 Contact: D. Brent Polk, University of Southern California and Children's Hospital Los Angeles...
BioCentury | Nov 7, 2011
Company News

NanoSmart, Children's Hospital Los Angeles deal

...will provide animal models. Details were not disclosed. NanoSmart Pharmaceuticals Inc. , Laguna Hills, Calif. Children's Hospital Los Angeles...
BioCentury | Jul 15, 2010
Cover Story

Zinc-ing differently about HIV

An industry-academic collaboration in California has yielded a practical gene therapy strategy for blocking HIV infection. With financial support from the California Institute for Regenerative Medicine , the team now is planning a clinical trial in...
BioCentury | Jun 3, 2010
Distillery Therapeutics

Indication: Infectious disease

Infectious disease Escherichia coli; meningitis Complement receptor 3 (CR3; CD11b); IL-10; prostaglandin E2 (PGE2) A study in mice suggests that increasing IL-10 or inhibiting PGE2 signaling could help treat neonatal meningitis caused by E. coli...
BioCentury | May 18, 2009
Company News

Children's Hospital Los Angeles, John Wayne Cancer Institute, National Institutes of Health cancer news

...leukemia, and in adults for solid tumors and blood cancers. Further terms were not disclosed. Children's Hospital Los Angeles...
BioCentury | Jun 11, 2007
Emerging Company Profile

Novelix Pharmaceuticals Inc.

...Tim Triche, Jonathan Buckley, Poul Sorensen and Nouri Neamati University collaborators: University of Southern California; Children's Hospital Los Angeles...
BioCentury | Aug 9, 1999
Company News

Childrens Hospital Los Angeles other research news

Childrens Hospital researchers and colleagues published in The Journal of Experimental Medicine the identification of EMAP II as an inhibitor of angiogenesis that acts by inducing apoptosis of blood vessel endothelial cells. The protein blocked...
BioCentury | Jun 28, 1999
Company News

BioSource, Childrens Hospital Los Angeles Research Institute deal

BIOI will receive right of first refusal to commercialize research tools developed at the institute. BIOI also will become the preferred vendor of immunological, cellular biological and molecular biological products to the institute. BIOI will...
Items per page:
1 - 10 of 11
BioCentury | Mar 19, 2015
Distillery Therapeutics

Therapeutics: CD19 ligand (CD19L); tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)

...et al. J. Clin. Invest.; published online Jan. 26, 2015 doi:10.1172/JCI76610 CONTACT: Fatih M. Uckun, Children's Hospital Los Angeles...
BioCentury | May 5, 2014
Product Development

Targeted cargo

...product, which delivers doxorubicin, is in preclinical testing to treat Ewing's sarcoma in partnership with Children's Hospital Los Angeles...
...LSE:AZN; NYSE:AZN), London, U.K. Bayer AG (Xetra:BAYN), Leverkusen, Germany Bind Therapeutics Inc. (NASDAQ:BIND), Cambridge, Mass. Children's Hospital Los Angeles...
BioCentury | Jul 26, 2012
Distillery Therapeutics

Indication: Various

...published online July 9, 2012; doi:10.1172/JCI62888 Contact: D. Brent Polk, University of Southern California and Children's Hospital Los Angeles...
BioCentury | Nov 7, 2011
Company News

NanoSmart, Children's Hospital Los Angeles deal

...will provide animal models. Details were not disclosed. NanoSmart Pharmaceuticals Inc. , Laguna Hills, Calif. Children's Hospital Los Angeles...
BioCentury | Jul 15, 2010
Cover Story

Zinc-ing differently about HIV

An industry-academic collaboration in California has yielded a practical gene therapy strategy for blocking HIV infection. With financial support from the California Institute for Regenerative Medicine , the team now is planning a clinical trial in...
BioCentury | Jun 3, 2010
Distillery Therapeutics

Indication: Infectious disease

Infectious disease Escherichia coli; meningitis Complement receptor 3 (CR3; CD11b); IL-10; prostaglandin E2 (PGE2) A study in mice suggests that increasing IL-10 or inhibiting PGE2 signaling could help treat neonatal meningitis caused by E. coli...
BioCentury | May 18, 2009
Company News

Children's Hospital Los Angeles, John Wayne Cancer Institute, National Institutes of Health cancer news

...leukemia, and in adults for solid tumors and blood cancers. Further terms were not disclosed. Children's Hospital Los Angeles...
BioCentury | Jun 11, 2007
Emerging Company Profile

Novelix Pharmaceuticals Inc.

...Tim Triche, Jonathan Buckley, Poul Sorensen and Nouri Neamati University collaborators: University of Southern California; Children's Hospital Los Angeles...
BioCentury | Aug 9, 1999
Company News

Childrens Hospital Los Angeles other research news

Childrens Hospital researchers and colleagues published in The Journal of Experimental Medicine the identification of EMAP II as an inhibitor of angiogenesis that acts by inducing apoptosis of blood vessel endothelial cells. The protein blocked...
BioCentury | Jun 28, 1999
Company News

BioSource, Childrens Hospital Los Angeles Research Institute deal

BIOI will receive right of first refusal to commercialize research tools developed at the institute. BIOI also will become the preferred vendor of immunological, cellular biological and molecular biological products to the institute. BIOI will...
Items per page:
1 - 10 of 11